What is Tempus AI Stock?


Tempus AI harnessing the power of artificial intelligence (AI) to transform patient care and redefine the future of precision medicine. With its recent initial public offering (IPO) and trading debut, Tempus AI has captured the attention of investors and industry experts alike, solidifying its position as a formidable force in the world of AI-driven healthcare solutions.

What Is Tempus AI?

Tempus AI, Inc. (ticker symbol: TEM) is a healthcare technology company that specializes in the application of artificial intelligence to medical data processing. The company’s mission is to revolutionize precision medicine by providing AI-enabled solutions that enhance patient care and facilitate the discovery, development, and delivery of optimal therapeutics.

IPO and Trading Debut

On June 14, 2024, Tempus AI celebrated a monumental milestone as it went public with an initial public offering (IPO) of 11.1 million shares of its Class A common stock, priced at an impressive $37 per share. The IPO raised approximately $410.7 million, valuing the company at around $6 billion, showcasing the immense potential and investor confidence in Tempus AI’s groundbreaking approach.

The stock began trading on the Nasdaq Global Select Market under the ticker symbol “TEM,” and its debut was nothing short of remarkable. On its first day of trading, Tempus AI’s stock opened at $40 per share and saw a significant surge, reaching a high of $43.88 before closing at $40.25. The stock experienced an impressive increase of up to 18% during its debut, reflecting the strong investor interest and excitement surrounding the company’s future prospects.

Stock Performance

Tempus AI’s stock performance has been closely watched by analysts and investors alike since its trading debut. While the company is not yet profitable, with significant losses reported in recent years, its innovative approach and disruptive potential have captured the imagination of the market.

Company Overview

Founded in 2015 and headquartered in Chicago, Illinois, Tempus AI has built one of the world’s largest libraries of clinical and molecular data. By harnessing the power of AI, the company provides cutting-edge precision medicine solutions to over 7,000 physicians across more than 2,000 healthcare institutions, including a significant number of academic medical centers in the U.S.

Tempus AI’s platform offers a range of services, including next-generation sequencing diagnostics, molecular genotyping, and clinical trial matching services. These solutions aim to personalize treatment plans, accelerate drug development, and improve patient outcomes by leveraging the insights derived from vast amounts of medical data.

Financial Metrics

Despite its impressive growth and innovative approach, Tempus AI’s financial metrics reveal a company in its early stages, with a focus on investing in research and development to drive future growth. For the trailing twelve months (ttm), the company reported revenues of $562.02 million and a net income loss of $293.25 million.

While operating at a loss is not uncommon for companies in the technology sector, particularly those focused on groundbreaking innovations, Tempus AI’s ability to generate sustainable revenue and achieve profitability will be a key factor in determining its long-term success.

Leadership and Ownership

Tempus AI was founded by Eric Lefkofsky, a serial entrepreneur and co-founder of the renowned deal-sharing platform Groupon. Lefkofsky remains a significant shareholder with substantial voting power post-IPO, demonstrating his ongoing commitment to the company’s vision and future growth.

In addition to Lefkofsky’s leadership, Tempus AI has garnered the support of prominent investors such as SoftBank Group and Google (Alphabet Inc.), further bolstering its financial resources and strategic positioning in the healthcare technology market.

Market Position and Competitors

Tempus AI operates in the highly competitive and rapidly evolving field of genomics and precision medicine, where it competes with established players such as Foundation Medicine, Caris Life Sciences, and Guardant Health. While these companies have a strong foothold in the market, Tempus AI’s AI-driven approach and strategic partnerships with major pharmaceutical companies position it as a disruptive force in the industry.

By leveraging its cutting-edge AI capabilities and vast data resources, Tempus AI aims to accelerate the development of personalized treatments, streamline clinical trials, and ultimately improve patient outcomes on a global scale.


Tempus AI’s IPO and trading debut have marked a significant milestone in the company’s journey, showcasing its potential to revolutionize the healthcare industry through the power of AI. With its innovative solutions, strategic partnerships, and visionary leadership, Tempus AI has positioned itself as a formidable player in the realm of precision medicine.

As the company continues to navigate the challenges of scaling its operations and achieving profitability, investors and industry experts alike will closely monitor its progress. One thing is certain: Tempus AI’s commitment to harnessing the power of AI to transform patient care and drive medical breakthroughs has the potential to reshape the future of healthcare as we know it.

Leave a Comment